A boy younger than age six with known Niemann-Pick disease type C (NPC) presented two years ago to his family physician with a rapid increase in abdominal girth in the preceding six weeks. Laboratory data revealed markedly increased aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and cholesterol. A sonogram was ordered to evaluate the liver and spleen.
Organomegaly was present in the liver, spleen, and kidneys. The liver was markedly enlarged, measuring 19.1 cm in the right lobe and 13.9 cm in the left lobe. Upper limits of normal for a patient this size are 13.1 cm for the right lobe and 9.97 cm for the left. The spleen was also enlarged, measuring 18.6 cm, with 8.06 cm being the average length. The kidneys were enlarged at almost two standard deviations from the mean. The liver was heterogeneous in appearance, with multiple hypoechoic masses throughout ( Fig. 1 ). Color Doppler sampling of the hepatic artery showed increased velocity at 134 cm/sec and normal portal vein flow at 24 cm/sec ( Fig. 2 ). Ascites were noted in Morrison's pouch. These findings were consistent with Niemann-Pick disease.
A sonogram one week later noted increased splenomegaly at 21.2 cm and retrograde portal vein flow. After a partial splenectomy, Doppler imaging demonstrated a partially thrombosed main portal vein, reversal of the intrahepatic portal vein branches, and hepatic arterial flow at 300 cm/sec ( Fig. 3 ). This was consistent with intrahepatic arteriovenous shunting.
The patient continued to have refractory ascites, which were treated aggressively with multiple therapeutic paracentesis. Lung nodules were noted on a chest x-ray and chest computerized tomography (CT) scan. An open lung biopsy and liver biopsy confirmed hepatocellular carcinoma (HCC), consequently making the patient ineligible for transplantation. These findings were consistent with advanced NPC. The patient expired two months after the initial sonogram.
Discussion
NPC has a prevalence of approximately 1 in 150,000 worldwide. 1 The incidence in early life is probably underestimated due to its nonspecific presentations. 2 All types of Niemann-Pick disease are autosomal recessive. Both parents carry one copy of the abnormal gene, without having any signs of the disease themselves. Children with Niemann-Pick disease have two copies of the abnormal gene. 3 Presentation of NPC in early life is nonspecific. NPC should be considered in infants presenting with clinical symptoms such as fetal ascites and neonatal liver disease, particularly when this is accompanied by jaundice, hepatosplenomegaly, pulmonary infiltrates, infantile hypotonia, and vertical supranuclear gaze palsy. NPC presentation in middle to late childhood includes clumsiness, gait disturbance, and seizures. Physical manifestations are accompanied by progressive cognitive impairment and behavioral disturbances, and it eventually becomes evident that the child is mentally deteriorating. Adolescents or adults may present with neurological disease as well, but with a much slower rate of progression. Older patients may also have apparent psychiatric illness, such as major depression or schizophrenia. 4 Diagnosis of NPC depends on the age of onset. Prenatal diagnosis for NPC can be attained by chorionic villi sampling (CVS) or amniocentesis. 5 These tests show accumulation of sphingomyelin in the affected fetus. Diagnosis of NPC after birth is confirmed by biochemical testing that is performed by taking a skin biopsy, growing the cells (fibroblasts) in the laboratory, and studying their ability to transport and store cholesterol. 6
Sonographic Evaluation
Although the diagnosis of NPC is confirmed by filipin staining of cultured fibroblasts (skin biopsy) and DNA mutation analysis, 7 the disease progression can be evaluated using sonography.
Sonography in early infancy and childhood can reveal abnormal echotexture and size of the liver and spleen. Findings of liver and spleen enlargement, HCC, ascites, and vessel patency changes demonstrate NPC. 6 Hepatocellular carcinoma is a common finding of NPC. It appears as multiple nodules or diffuse infiltration of the liver. There is also a propensity toward venous invasion. The portal vein is involved more commonly than the hepatic venous system, occurring in 30% to 60% of HCC findings. In a patient with NPC, the sonographic appearance of the liver reveals hypoechoic, complex, or echogenic masses relating to HCC. 8 Splenomegaly is also indicative of NPC. Increased spleen size is due to portal hypertension. Thrombosis of the portal venous system occurs secondary to the hepatocellular carcinoma. 8 These sonographic findings aid in evaluating NPC disease advancement.
Prognosis
The disease progression of patients with NPC is variable. 9 By age three, 85% of infants die from pneumonia or liver disease. Children and adolescents experience progressive neuromuscular problems, dementia, and pneumonia and die at ages 20 to 30. Adults experience a slow-progressing neuro-logical disorder and mental illness and may live to old age. 1
Treatment/Therapy
No specific treatment or definitive therapy for NPC exists. A healthy, low-cholesterol diet is encouraged; however, research into low-cholesterol diets and cholesterol-lowering drugs does not indicate that these halt the progress of the disease or change cholesterol metabolism at the cellular level. A trial of cholesterol-lowering agents showed that the amount of free cholesterol in the liver of patients with NPC could be reduced by the administration of cholestyramine, lavastatin, and nicotinic acid, but there is no evidence that this approach modifies the neurological progression of NPC. In addition, liver transplantation corrects hepatic dysfunction but does not improve the neurological aspect of the disease. Symptomatic therapy, such as medications, may be somewhat effective in the management of seizures, dystonia, and cataplexy. 3 All treatment modalities, including bone marrow transplantation, liver transplantation, and aggressive cholesterol-lowering therapy, have proven ineffective. Inhibition of glycosphingolipid synthesis has been shown to delay onset and prolong survival in NPC, and therapeutic trials are presently being planned. At best, such a therapy would slow the progression of Niemann-Pick disease. 2
Genetic Counseling: Risk to Family Members
NPC is inherited in an autosomal recessive manner. A total of 31 mutations of the NPC-1 gene are known to cause the disease. 1 Couples who have had a child with NPC are at a 25% risk in each pregnancy of having an affected child. The phenotype usually runs true in families. Unaffected siblings who are older than the proband have a two-thirds risk of carrying one abnormal allele. Genetic counseling is a way of providing individuals and families with information on the nature, inheritance, and implications of Niemann-Pick disease to help them make informed medical and personal decisions. 4
Summary
In the clinical setting of neonatal hepatitis, hepatosplenomegaly, and undiagnosed neurological symptoms, NPC disease should be considered as a possible diagnosis. 10 Skin biopsy and DNA mutation analysis are effective screening tests to make a definitive diagnosis. Sonography plays a role in following the progression of NPC. It can be used to assess the progression of the disease in the liver, as well as vascular changes associated with portal hypertension. With no present cure for NPC, sonography will continue to provide valuable diagnostic information to aid in following the progression of this deadly disease.
